Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 2/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.36 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.31 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.31 |
| ▸ | BLM | P54132 | 1/20 | 0.31 |
| ▸ | VCP | P55072 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13777716 | 0.89 | ADORA3 (0.32) | ADORA2AADORA3ADORA1 | |
| SCHEMBL13777764 | 0.83 | PDE3A (0.34) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL13777763 | 0.81 | ADORA2A (0.34) | ADORA2AADORA3ADORA1 | |
| SCHEMBL13625768 | 0.80 | ADORA3 (0.32) | ADORA3MEN1ALDH1A1LMNACYP3A4 | |
| SCHEMBL13625769 | 0.80 | GRIN2B (0.40) | CYP3A4SMN1; SMN2 | |
| SCHEMBL13819681 | 0.80 | ACACB (0.32) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL13625863 | 0.80 | ADORA3 (0.36) | ADORA2AADORA3MEN1ALDH1A1KMT2A | |
| SCHEMBL12010054 | 0.79 | MEN1 (0.31) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL13819686 | 0.79 | MEN1 (0.31) | MEN1ALDH1A1LMNACYP3A4NFKB1 | |
| SCHEMBL13819443 | 0.79 | MEN1 (0.32) | MEN1ALDH1A1LMNACYP3A4NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-07-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090170803-A1 | ADJUNCTIVE TREATMENT OF BIOLOGICAL DISEASES | ADORA2A, PDE4A, PDE4B | ADORA2A 1/4885ADORA3 7/4885ADORA1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.